Vice President, Injection Systems
The Datwyler Group is proceeding with a $100-million investment for a new manufacturing facility for elastomer components, outlined Megan Williamson, Vice President, Injection Systems, Datwyler at the DCAT Member Company Announcement Forum that was held on Monday March 20 at DCAT Week ’17. The $100-million investment, the largest in the company’s history, will be used to fund a new facility in Middletown, Delaware.
The facility will be one of Datwyler’s key manufacturing plants worldwide and its third facility in the US. In December 2016, the company broke ground for the new facility. Production is scheduled to start in the first half of 2018, and the plant will be fully operational by the end of 2018. The facility will cover approximately 200,000 square feet in total. In Phase One of the construction, Datwyler will be able to produce up to 1 billion components per year. In Phase Two, at full capacity, the facility will be able toproduce at least 2 billion components per year. The new facility will produce elastomeric compounds for pharmaceutical components in line with Datwyler’s First Line standard. The First Line standard results from the company’s cleanroom manufacturing concept based on a fully integrated good manufacturing practice (GMP) environment.
The facility is part of the health care unit of the Datwyler Sealing Solutions Division, which designs, develops, and manufactures specialized and complex, and unique coatings, elastomer formulations, and aluminum seals for injectable packaging and drug-delivery systems. Datwyler has been present in the US since 1981 and is headquartered in Altdorf, Switzerland.